不典型性脑膜瘤52例CT诊断分析

回顾性分析了22例少见部位的脑膜瘤，22例CT表现不典型及8例CT误诊脑膜瘤的CT表现，以确定脑膜瘤不典型表现与CT误诊的关系。结果显示脑膜瘤的CT误诊多数缘于经验不足与疏忽，少数为极不典型表现所致。若检查全面、阅片仔细．术前CT定性率可由90％提高至96．25％。     

内侧型蝶骨嵴脑膜瘤的显微外科治疗

目的 提高内侧型蝶骨嵴脑膜瘤的全切率,降低病死率和致残率.方法 对25例内侧型蝶骨嵴脑膜瘤显微外科治疗病例的临床资料进行回顾性分析.结果 冠状位计算机体层摄影术有助于判断肿瘤的生长点.磁共振成像可显示肿瘤与海绵窦、颈内动脉的关系.1例肿瘤侵入海绵窦,11例肿瘤包绕颈内动脉和主要分支.肿瘤附着点为前床突和(或)小翼的内侧.18例达Simpson Ⅰ、Ⅱ级全切除.无手术死亡,疗效满意.结论 显微手术可明显提高肿瘤全切率,减少术后并发症,降低病死率.手术要点是尽早离断肿瘤基底并沿颈内动脉床突上段由近向远分离切除包绕的肿瘤.由于多数存在肿瘤与血管之间的蛛网膜界面,提倡在第1次手术中采用积极的显微外科治疗.     

细胞增殖特性与良性脑膜瘤复发的关系

目的 :探索良性脑膜瘤的复发与肿瘤细胞增殖能力的关系 ,并寻找能预测其复发的指标。　方法 :对 1 5例复发的良性脑膜瘤和 2 2例非复发的良性脑膜瘤共 4 9份标本分别进行增殖细胞核抗原 (PCNA)和Ki 6 7的免疫组化染色 ,计数阳性细胞数的比率即标记指数 (LI) ,比较各组间的PCNALI和Ki 6 7LI。　结果 :复发的良性脑膜瘤的PCNALI和Ki 6 7LI均显著高于未复发组 (P <0 .0 5 ) ;复发组中同一患者前后两次手术标本的PCNALI和Ki 6 7LI均无显著差异 (P >0 .0 5 )。　结论 :复发的良性脑膜瘤的细胞增殖性高于未复发组 ,当PCNALI>2 .0 %时 ,提示肿瘤有复发倾向。良性脑膜瘤复发后其增殖特性无明显改变     

某区医院发热伴呼吸道症状病人临床分析

目的：探讨常见呼吸道发热疾病的临床特点及与传染性非典型肺炎(严重急性呼吸综合症，SAGS)的鉴别。方法：发热门诊诊治的以发热体温高于38℃伴呼吸道症状患者702例，对病因、临床表现、实验室检查、胸部X线、治疗及转归进行比较。结果：常见呼吸道发热患者中，急性上呼吸道感染596例占总数的85％，577病例白细胞计数不高占82％，淋巴细胞计数不降低，X线检查正常或仅有支气管炎表现。有基础肺部或全身疾病患者，虽然有发热，但往往以肺部或全身原发疾病相应症状为重要或首发表现，可有气急，体温以中度发热为主，78％病例有白细胞计数及中性比例升高。胸片除肺炎改变外，多有肺部基础疾病的表现，抗生素治疗有效；而单纯性肺炎胸部X线多表现为节段性或局灶性肺炎。这部分病例也以发热为主要或首发症状，一般表现为咳嗽、咳痰，气急少见，易与SARS混淆。结论：临床呼吸道发热疾病以急性上呼吸道感染最多见，容易忽略，要注意筛查。单纯性肺炎与SARS的鉴别，应结合流行病史、治疗反应及实验室检查结果进行。     

跨矢状窦脑膜瘤术中矢状窦的处理

目的总结跨矢状窦脑膜瘤术中矢状窦的处理方法.方法对26例跨矢状窦脑膜瘤及受累矢状窦进行切除,依具体情况重建或不重建矢状窦.结果该组病人无手术死亡,手术后均未加重原有神经功能障碍,无脑血液回流障碍,7例重建矢状窦者未发现有矢状窦内血栓形成.结论矢状窦旁脑膜瘤的治疗除肿瘤切除外,对受累上矢状窦处理是否彻底对预防术后复发是至关重要的.对受累矢状窦应按具体情况按一定的原则进行积极处理.     

Mechanisms of Panax ginseng in preventing rat pheochromocytoma cells from apoptosis

Aims of the study

Although ginseng root possesses dominant central therapeutic effects and has recently undergone investigations for treating different neuronal diseases, most of its mechanisms are still unknown. Therefore, the neuroprotective mechanisms of ginseng were studied.

Materials and methods

The protection afforded by different methanol extracts of Panax ginseng (PG) was tested in a serum deprivation-induced apoptotic model using neuronal-like pheochromocytoma (PC12) cells. An MTT assay, annexin V-FITC staining, and Western blots were, respectively, applied to identify the viability of cells, the apoptotic form of cell death, and the activity of antiapoptotic signaling.

Results

The known antiapoptotic PI3-K/Akt and MEK/ERK pathways in this system were ruled out due to failure of LY 294002 and PD 98059 to block the protection by PG. A protein kinase A (PKA) inhibitor was found to block the protection by PG and PG-induced CREB phosphorylation, suggesting that the PKA/CREB pathway mediates the protective effect of PG. Downregulation of classical and novel PKCs failed to block the protection by PG, while an atypical PKC inhibitor blocked protection by PG.

Conclusions

PKA and atypical PKC are important for the protection afforded by PG in preventing serum deprivation-induced PC12 cell apoptosis.     

89例小脑幕脑膜瘤的显微外科手术治疗

目的 总结小脑幕脑膜瘤的手术治疗经验。方法 回顾分析1993年5月-2006年5月，89例经手术治疗的小脑幕脑膜瘤病人的临床表现、影像学检查、手术记录、病理及术后早期并发症。常见症状是头痛（54例，60．7％）、头晕（29例，32．6％）、步态异常（34例，38．2％）、听力损害（27例，30．3％）及面部疼痛（20例，22．5％）。主要体征是共济失调（38例，42．7％）、运动和感觉障碍（31例，34．8％）及脑神经损害（48例，53．9％）。多数病例MRI表现为等T1、T2信号并明显均一强化。结果 本组全切除65例（73．0％），次全切除23例（Okudera-KobayashiⅣ—Ⅴ级）。手术并发症的发生率和病死率分别为22．5％和1．1％。结论 根据小脑幕脑膜瘤部位以及与周围神经血管关系选择最佳手术入路。如全切肿瘤可能带来重要的神经功能损害，应考虑残留部分肿瘤。     

神经内镜辅助眶上锁孔入路治疗巨大嗅沟脑膜瘤

目的探讨神经内镜辅助眶上锁孔入路治疗巨大嗅沟脑膜瘤的手术效果及手术技巧。方法采用内镜辅助、眶上锁孔入路（显微手术）治疗12例巨大（≥7cm）嗅沟脑膜瘤。结果肿瘤全切除9例（SimpsonⅠ级切除5例，Ⅱ级切除4例），次全切除（SimpsonⅢ级切除）3例。无手术死亡。10例随访3个月～2年，平均14个月。9例恢复正常生活，1例生活能自理。NRI随访9例，肿瘤无复发。结论利用神经内镜辅助及显微外科技术，采用眶上锁孔入路、对肿瘤进行分块切除治疗巨大嗅沟脑膜瘤，手术创伤小，疗效满意。     

嗅沟脑膜瘤术式选择及长期临床预后随访

目的分析嗅沟脑膜瘤的手术治疗和随访结果。方法收集20例嗅沟脑膜瘤手术病例,并分析其临床表现及随访结果。结果嗅沟脑膜瘤大多以精神症状、视觉障碍和嗅觉减退为首发症状,9例行冠状切口,4例行半冠状切口,分块切除肿瘤,5例翼点入路,1例纵裂入路。1例眶上入路,SimpsonI级切除6例。SimpsonⅡ级切除13例,SimpsonⅢ级切除1例,预后良好,1例复发。随访时间1~6年(平均3.1年),术前术后均保留嗅觉的为2例,精神状态改善18(91%)和视力障碍改善的15(75%)。1例(5%)复发再次手术。结论术式的选择取决诸多因素,预后取决于手术中的组织保护。     

Potential doubling time and tumour doubling time in meningiomas and neurinomas

Summary Cell kinetic study plays an important role in treatment planning of brain tumour patients. MIB-1 antibody has recently become available, which detects Ki-67 antigen even in the formalin-fixed paraffin-embedded specimens. We performed MIB-1 immunostaining in 50 meningiomas and 50 neurinomas, and estimated the cell cycle time (tc) and potential doubling time (Tpot) from MIB-1 staining index (MIB-1 SI) and mitotic index (MI). MIB-1 SI logarithmically correlated with MI in both meningiomas and neurinomas. The tc and the Tpot were expressed as a function of the mitosis time (tm), while the tm is known to be around one hour and not exceeding two hours. When the tm was assumed to be one hour, the average tcs of meningiomas and neurinomas were 6.53±3.56 days and 7.67±3.27 days, respectively. The Tpots were447 × (MIB-1 SI)^–1.29 × tm in meningiomas, and490 × (MIB-1 SI) ^–0.98 × tm in neurinomas.The tumour doubling times (Tds) were calculated from serial imaging studies in 22 neurinomas and 15 meningiomas. The Tds were formulated as794 × (MIB-1 SI) ^–0.83 in meningiomas and1380 × (MIB-1 SI) ^–0.97 in neurinomas. Most of the Tds correlated well with the Tpots in meningiomas and neurinomas, and exceeded values of the Tpot when the tm is assumed to be one hour, although a few tumours showed unexpectedly longer Tds. The Tpot and the tc estimated from MIB-1 SI and MI are clinically useful parameters for predicting the growth potential of meningiomas and neurinomas where no other simple methods are available.